ARVN Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 4.36%, SMA50 7.61%, SMA200 40.5%). The stock’s 14-day RSI is 58.04 (neutral), while the ATR of 0.79 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.32% below its high and over 126.78% above its low. Average 10-day trading volume of 819.20 thousand shares is in line with the 3-month average of 840.72 thousand, indicating normal recent market interest.

Arvinas, Inc. has 63.96 million shares outstanding. The public float is 55.36 million shares, elevated short interest at 7.62% of float. This equals 4.79 million shares. The short ratio is 5.63 days. Institutional investors hold 104.72% of the float. Insiders own 7.88%. SHANNON TIMOTHY M holds 1.65 million shares, Houston John G has 1.12 million shares and Berkowitz Noah has 202.50 thousand shares. Over the past six months, insider transactions show net selling. They sold 46.48 thousand shares across 10 transactions.

Arvinas, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$17.57. This means the shares are trading below this model’s fair value.

Arvinas, Inc. (NASDAQ:ARVN) closed at $10.11 USD, losing -$0.08 (-0.79%) from the previous close of $10.19. The stock is currently mid-range between its 52-week high and low $5.90 and $14.51. With a market capitalization of about $646.65 million, Arvinas, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.80). Key stats such as the average daily volume over the past year has been around 875.18 thousand shares, volume is running light vs its 52-week average. Headquartered in New Haven, CT, Arvinas, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Randy Teel, the company employs approximately 430 people and listed since September 27, 2018. Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Arvinas, Inc. generated EPS of -$1.22 over the past year. Five-year average earnings growth is 17.7%. Wall Street analysts project EPS growth of -27.17% annually over the next five years. The latest quarter delivered EPS of -$1.10. The next quarter is forecast at -$0.93. Next year's EPS is expected at -$37.32. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 9 Buy ratings, 1 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $6.00. The high target offers 137.39% upside. The low target suggests -40.65% downside. The mean target is $15.85. This offers 56.78% upside. Arvinas, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended February 24, 2026, missed forecasts by 100.0%. The prior quarter beat by -35.8%. Over the last six quarters, Apple has recorded several small beats. These include -22.73% in October 30, 2024.

Arvinas, Inc. trades at a P/E ratio of -8.07, slightly below the S&P 500 average, with a price-to-sales ratio of 2.45 and a price-to-book ratio of 1.5 suggesting the stock is closer to book value. The P/FCF stands at -2.33, also below market averages.

Our AI price prediction model suggests that Arvinas, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.87%, with price expected at $9.82 by May 22, 2026, within a range of $9.25 to $10.42 3-Month Outlook: Projected rise of 110.88%, reaching $21.32 by August 06, 2026, with a range of $20.56 to $22.05. 1-Year Outlook: Projected gain of 56.58%, with price at $15.83 by May 07, 2027, within a range of $0.00 to $28.43.

Arvinas, Inc. (NASDAQ:ARVN) shares are flat 1.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Arvinas, Inc. trading at a premium to the broader market with a P/E of -8.07. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $53.62, suggesting 430.37% upside. Our AI forecast model points to short-term weakness (-2.87% over two weeks), a medium-term rise (110.88% over three months), and a longer-term gain (56.58% over one year), with expected trading ranges indicating moderate volatility.